The immunomodulatory effects of barettin and involvement of the kinases CAMK1α and RIPK2

Immunopharmacol Immunotoxicol. 2015;37(5):458-64. doi: 10.3109/08923973.2015.1082584.

Abstract

Background: Barettin is a marine natural compound with reported anti-inflammatory and antioxidant properties. The combination of these effects led us to explore barettin further as an inhibitor of atherosclerosis development.

Methods: The effect of barettin on MCP-1 and IL-10 secretion from activated immune cells was detected by ELISA. Determination of cell viability of oxidized low-density lipoprotein (oxLDL) and barettin exposed HUVEC cells were investigated by using CellTiter 96® AQ(ueous) One Solution. The kinase inhibition assays were performed using a radioactive ((33)P-ATP) filter binding assay at the University of Dundee, UK.

Results: Barettin reduces the secretion of monocyte chemotactic protein-1 (MCP-1) from LPS-stimulated monocytes, but was not able to prevent oxLDL-induced cell death in HUVEC. Barettin has inhibitory activity against two protein kinases related to inflammation, namely the receptor-interacting serine/threonine kinase 2 (RIPK2) and calcium/calmodulin-dependent protein kinase 1α (CAMK1α). We also demonstrate that barettin reduce the production of the anti-inflammatory cytokine interleukin-10 (IL-10) in a dose and time-dependent manner, possibly by inhibiting CAMK1α.

Conclusions: The anti-inflammatory activity of barettin is exerted through the regulation of inflammatory mediators such as MCP-1 and IL-10, possibly via inhibition of kinases.

Keywords: Antioxidant; IL-10; IL-1β; cytokines; marine natural compound.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 1 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 1 / immunology*
  • Cell Line, Tumor
  • Chemokine CCL2 / immunology
  • Human Umbilical Vein Endothelial Cells / cytology
  • Human Umbilical Vein Endothelial Cells / immunology*
  • Humans
  • Immunologic Factors / pharmacology*
  • Interleukin-10 / immunology
  • Peptides, Cyclic / pharmacology*
  • Protein Kinase Inhibitors / pharmacology*
  • Receptor-Interacting Protein Serine-Threonine Kinase 2 / antagonists & inhibitors
  • Receptor-Interacting Protein Serine-Threonine Kinase 2 / immunology*

Substances

  • Anti-Inflammatory Agents
  • CCL2 protein, human
  • Chemokine CCL2
  • IL10 protein, human
  • Immunologic Factors
  • Peptides, Cyclic
  • Protein Kinase Inhibitors
  • barettin
  • Interleukin-10
  • RIPK2 protein, human
  • Receptor-Interacting Protein Serine-Threonine Kinase 2
  • CAMK1 protein, human
  • Calcium-Calmodulin-Dependent Protein Kinase Type 1